This portal uses its own or third-party cookies for analytical purposes, as well as links to third-party portals in order to share content on social networks. You can get more information in the <a href="https://pro-assets-usc.azureedge.net/en/legal-notice">cookies policy</a>.
    Research infrastructures

    INNOPHARMA

    Imaxe representativa
    The INNOPHARMA Drug Screening and Pharmacogenomics Platform

    REACT-EU PROJECT
    CONVENIO DE COLABORACIÓN ENTRE A AXENCIA GALEGA DE INNOVACIÓN E A UNIVERSIDADE DE SANTIAGO DE COMPOSTELA PARA REGULAR AS CONDICIÓNS DA AXUDA DESTINADA Á ACTUALIZACIÓN E AMPLIACIÓN DA PLATAFORMA INNOPHARMA DA USC
    Click for more Info

    The INNOPHARMA Drug Screening and Pharmacogenomics Platform arises from the BioFarma group's accumulated experience of more than 20 years in continuing programs, testing hundreds of thousands of compounds, tens of targets and the development, automation and implementation of hundreds of assays in complete cascades of early drug discovery.

    The high-capacity infrastructures owned by INNOPHARMA allow it to be a European reference in early drug discovery, being accredited as one of the seven high-capacity nodes of the European Research Infrastructure Consortium (ERIC) EU-OPENSCREEN. INNOPHARMA Platform offers a set of services that cover all stages of the early drug discovery process from target identification to preliminary safety and toxicity assessment.

    The platform is available for both on-demand services and complementary collaborative projects in drug discovery.

    • Drug discovery program design

      • Candidate Target Profile definition
      • Feasibility/druggability assessment
      • Screening cascade design
      • Identification of hits, leads and candidates

      Assay development, miniaturization, and automation

      • Target-based assays
      • Phenotypic assays
      • Deconvolution assays
      • Custom assays

      De-risking programs

      • Drug discovery programs up to proof of concept stage

      Chemical compound libraries

      • Compounds selected in silico based on biological and structural diversity
      • Proprietary compounds
      • Drug repurposing libraries
      • Target-focused sub-libraries

      Pharmacogenomics studies

      • Biomarkers identification
      • Identification of novel therapeutic targets

      In vitro preliminary ADME-Tox and safety

      • Cytochrome P450 induction and inhibition
      • Cytotoxicity
      • hERG channel
      • Chemical, microsomal and plasma stability
      • Plasma protein binding
      • Permeability assay
      • P-glycoprotein
      • Genotoxicity

      Customized assay development

      • Target engagement
      • Phenotypic assays
      • Deconvolution assays

    • From INNOPHARMA we are constantly developing new tests and implementing new technologies, so if you have any interest in any test or technology not included in this list, please contact us

      COVID-19

      • IN VITRO ASSAYS
      		ACE2 activity
      TMPRSS2 activity
      Furin activity

      TARGET-BASED

      • GPCRs
      Radioligand Assays
      Adenosine
      		A1
      A2A
      A2B
      A3      		   Dopamine
      		D1
      D2
      D3
      D4
      D5
      Histamine
      		H1
      H2
      H3      		   Adrenergic:
      		α1
      α2
      α2C
      β1
      β2
      β3
      Serotonin
      		5-HT1A   5-HT1B   5-HT1D
      5-HT2A  5-HT2B  5- HT2C
      5-HT5A   5-HT6   5-HT7      		   Cannabinoid:
      		CB1
      CB2
      Muscarinic:
      		M1
      M2
      M3
      M4
      M5
       
      Second Messengers
      Arachidonic acid metabolism
      Nitric oxide synthase
      Inositol phosphate
      Calcium mobilization
      		   Isolated Organ Assays
      Adenosine: A1 A2A A2B
      Adrenergic: α1 α2 β1
      Histamine: H1 H2
      Muscarinic: M1 M2 M3
      Serotonin: 5-HT2A 5-HT2B 5-HT3 5-HT4
      Beta-Arrestin Translocation - BRET
      Mu-opioid
      CX3CR1
      • TRANSPORTERS
      		Radioligand Assays
      Dopamine (DAT)
      Noradrenaline (NAT)
      Serotonin (5-HTT)
      • NUCLEAR RECEPTORS
      Radioligand Assays
      		Estrogen receptors (ER)
      Androgen receptor (AR)
      Progesterone receptor (PR)
      Glucocorticoid receptor (GR)
      Peroxisome proliferator-activated receptors (PPAR)
      Prostanoid receptors (PR)
      Functional assays
      		Androgen receptor (AR)
      Glucocorticoid receptor (GR)

       

      • ENZYMES
      Kinase profiling >  250 functional assays
      Phosphodiesterases: 15 activity assays
      Phosphatases
      Beta-secretase
      Acetylcholinesterase  
      Monoamine oxidases: MAO-A, MAO-B
      Epigenetic enzymes    
      • ION CHANNELS
      Voltage-gated
      		Calcium
      Potasium
      Sodium
      hERG
      Membrane ligand-gated
      		NMDA
      GABAA
      5-HT3

      PHENOTYPIC ASSAYS

      • CELL VIABILITY AND CYTOTOXICITY IN 20+ HUMAN CELL LINES
      • MORPHOLOGICAL PROFILING BY HIGH-CONTENT IMAGING (CELL PAINTING)
      • PHENOTYPIC PROFILING BY LABEL-FREE DYNAMIC MASS REDISTRIBUTION-BASED ASSAYS
      • TARGET-DECONVOLUTION STRATEGIES
      • IN VITRO TRANSLATIONAL DISEASE-RELATED ASSAYS
      Neurological and neurodegenerative diseases
      		Neurite outgrowth
      α-synuclein aggregation
      Metabolic- disease
      		Adipocyte assay

      PRELIMINARY ADME-Tox AND SAFETY ASSAYS

      • CITOTOXICITY
      Cell Lines
      Cancer cell lines
      		Human ovarian carcinoma: A2780, A2780cis, NCI-ADR/RES
      Human cervix carcinoma: HeLa 229
      Human breast carcinoma: MCF-7, T47D, MDA-MB-231, Hs578T
      Human lung carcinoma: NCI-H460, A549
      Human glioblastoma: SF268
      Human colon carcinoma: CACO-2, HT-29, HCT116
      Human liver carcinoma: Hep-G2
      Human neuroblastoma: SH-SY5Y
      Human acute myeloid leukemia: HL-60
      Human pancreatic carcinoma: CFPAC-1
      Human prostate carcinoma: LNCaP, PC3
      Human osteosarcoma: U2OS
      Other cell lines
      		Human lung fibroblasts: MRC-5
      Porcine kidney cell line: LLC-PK1
      Cell Viability Technologies
      Crystal violet
      MTT reduction
      Sulforhodamine B
      ATP production
      • CYTOCHROME INDUCTION AND INHIBITION
      Recombinant P450 (1A2, 2C9, 2C19, 2D6, 3A4)
      • hERG
      • CHANNEL PERMEABILITY ASSAYS
      CACO-2 (6-well, 24-well and 96-well formats)
      • P-GLYCOPROTEIN SUBSTRATE
      • SOLUBILITY ASSAYS
      Aqueous solubility (pH-dependent)
      • MICROSOMAL STABILITY
      In several species
      • PLASMA PROTEIN BINDING
      In several species
      • PLASMA STABILITY
      In several species
      • GENOTOXICITY
      Micronucleus assay

      CUSTOMIZED ASSAYS

      • AD-HOC ASSAY DEVELOPMENT AND SCREENING
      Target engagement
      Phenotypic assays
      Target deconvolution strategies

    • The Innopharma Platform has state-of the art equipment for carrying out assay development projects and screening campaigns with different technological approaches

      • Radioactivity (Filtration and SPA)
      • Absorbance
      • Fluorescence intensity and polarization
      • Luminescence
      • FRET and Homogeneous Time-Resolved Fluorescence
      • BRET
      • Alphascreen
      • Fluorescence Lifetime Imaging
      • Automated patch-clamp
      • Label free (Dynamic Mass Redistribution)
      • Automated mobility shift (Lab on a chip)
      • High Content Screening
      • UPLC-MS/MS
      • Genome wide and candidate gene association studies
      • Next Generation Sequencing

    • Click to see your rates

    • INNOPHARMA's Drug Screening and Pharmacogenomics Platform

      Molecular Medicine and Chronic Diseases Research Center (CIMUS)
    The contents of this page were updated on 10.02.2024.